Lack of association of CYP3A4-V polymorphism with the risk of treatment-related leukemia

Leukemia Research

Volumn 29, Issue 5, 2005, Pages 595-597

  Collado, María ^a   Barragan, Eva ^a   Calasanz, María J ^b   Larrayoz, María J ^b   Colomer, Dolors ^c   Munarriz, Blanca ^a   Verdeguer, Amparo ^a   Gutierrez, Antonio ^d   Batlle, Montserrat ^e   Sanz, Miguel A ^a   Bolufer, Pascual ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

^d HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^e HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A4; DRUG METABOLIZING ENZYME;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ALLELE; CANCER RISK; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENETIC RISK; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; GENOTYPE; HUMAN; LETTER; LEUKEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

EID: 20044380127     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2004.11.001     Document Type: Letter

References (9)

1. E. Friche, M.K. Danks, and W.T. Beck Characterization of tumor cell resistance to 4′-deoxy-4′-iododoxorubicin developed in Ehrlich ascites cells in vivo Cancer Res 52 1992 5701 5706
2. T.R. Rebbeck, J.M. Jaffe, A.H. Walker, A.J. Wein, and S.B. Malkowicz Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4 J Natl Cancer Inst 990 1998 1225 1229
3. C.A. Felix, A.H. Walker, B.J. Lange, T.M. Williams, N.J. Winick, and N.V. Cheung Association of CYP3A4 genotype with treatment-related leukemia Proc Natl Acad Sci USA 95 1998 13176 13181
4. N. Von Ahsen, M. Richter, C. Grupp, B. Ringe, M. Oellerich, and V.W. Amstrong No influence of the MDR-I C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A through concentrations or rejection incidence in stable renal transplant recipients Clin Chem 47 2001 1048 1052
5. van Schaik RHN, S.N. de Wildt, N.M. van Iperen, A.G. Uitterlinden, J.N. van den Anker, and J. Lindemans CYP3A4-V polymorphism detection by PCR-restriction fragment length polymorphism analysis and its allelic frequency among 199 Dutch caucasians Clin Chem 46 2000 1834 1836
6. C.M. Zeigler-Johnson, A.H. Walker, B. Mancke, E. Spangler, M. Jalloh, and S. Mc Bridge Ethnic differences in the frequency of prostate cancer susceptibility alleles at SRD5A2 and CYP3A4 Hum Hered 54 2002 13 21
7. J.G. Blanco, M.J. Edick, M.L. Hancock, N.J. Winick, T. Dervieux, and M.D. Amylon Genetic polymorphisms in CYP3A5 CYP3A4 and NQO1 in children who developed therapy-related myeloid malignancies Pharmacogenetics 12 2002 605 611
8. Y. Ando, T. Tateishi, Y. Sekido, T. Yamamoto, T. Satoh, and Y. Hasegawa Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4 J Natl Cancer Inst 91 1999 1587 1590
9. B. Amirimani, A.H. Walker, B.L. Weber, and T.R. Rebbeck RESPONSE: re: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4 J Natl Cancer Inst 91 1999 1588 1590